Clinical trials: IgAN - IgA Nephropathy
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunoglobulin A Nephropathy
Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy
The purpose of this study is to assess the efficacy and safety of SM101 in the treatment of Immunoglobulin A nephropathy (IgAN)
- Trial name
- NCT02605525
- Testing
- SM101
- Sponsor
- Baxalta now part of Shire
Cutaneous Vasculitis
IgA-positive Versus IgA-negative Immune Complex Vasculitis
Cutaneous vasculitis due to vascular deposition of large circulating immune complexes is a disease frequently seen by general practitioners and dermatologists.
- Trial name
- NCT01815190
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Glomerulonephritis , IGA
The Clinical Trial of ADR-001 for IgA Nephropathy
The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients.
- Trial name
- NCT04342325
- Testing
- infusion of ADR-001 (Mesenchymal stem cell)
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Nagoya University
IgA Nephropathy (IgAN), Membranous Nephropathy
Raman Spectroscopy Diagnosis of Kidney Diseases
This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental…
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, Diabetic Nephropathy, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT06760845
- Testing
- Imaging Time
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zunsong Wang
IgA Nephropathy, Glomerular Diseases
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with…
- Trial name
- INTEREST (NCT02954419)
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-sen University
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
A Study of Zigakibart in Adults With IgA Nephropathy
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
- Trial name
- NCT05852938
- Testing
- BION-1301
- Where
- 200 sites in United States, Argentina and 21 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN)
An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)
In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid .
- Trial name
- NCT01269021
- Testing
- mycophenolate mofetil plus lower dose of Prednisone, Prednisone in full dose
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Zhi-Hong Liu, M.D.
IgA Nephropathy
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin…
- Trial name
- NCT05775042
- Testing
- CM338
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Keymed Biosciences Co.Ltd
Immunoglobulin A (IgA) Nephropathy
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
- Trial name
- IGNAZ (NCT05065970)
- Testing
- Felzartamab
- Where
- 59 sites in United States, Australia and 13 more
- Volunteers
- 54 people
- Sponsor
- HI-Bio, A Biogen Company
Glomerulonephritis, Autoimmune Diseases
Calcitriol in the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A (IgA) nephropathy is the common primary glomerulonephritis in the world. Much literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular mesangial cell…
- Trial name
- NCT00862693
- Testing
- Calcitriol
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University First Hospital
IgA Nephropathy
Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy
This study is testing whether a medicine called mycophenolate mofetil (MMF) works better than the usual treatment for people whose kidney disease, called IgA nephropathy, has not improved with standard care.
- Trial name
- NCT07785128
- Testing
- Mycophenolate Mofetil (MMF), Prednisolon
- Where
- 3 sites in Bangladesh
- Volunteers
- 104 people
- Sponsor
- Shaheed Suhrawardy Medical College and Hospital
IgAN
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients.
- Trial name
- NCT07606352
- Testing
- STL303
- Where
- 8 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Sitala Bio LTD
IgA Nephropathy (IgAN), C3 Glomerulopathy
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis.
- Conditions
- IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
- Trial name
- NCT06786338
- Testing
- SGB-9768
- Where
- 11 sites in China
- Volunteers
- 45 people
- Sponsor
- Suzhou Sanegene Bio Inc.
Primary IgA Nephropathy
A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.
- Trial name
- NCT06137768
- Testing
- HRS-5965
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
IgA Nephropathy (IgAN)
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is…
- Trial name
- NCT07305974
- Testing
- RG002C0106
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
IgA Nephropathy (IgAN), Berger Disease
Monthly Dosing of Atacicept in IgAN
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
- Trial name
- NCT07020923
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Vera Therapeutics, Inc.
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.